Market Cap (In HKD)
5.48 Billion
Revenue (In HKD)
225.35 Million
Net Income (In HKD)
-22.09 Million
Avg. Volume
2.88 Million
- Currency
- HKD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 2.16-6.5
- PE
- -
- EPS
- -
- Beta Value
- -0.246
- ISIN
- CNE100004SM4
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Ziye Sui M.D., Ph.D.
- Employee Count
- -
- Website
- https://www.lepubiopharma.com
- Ipo Date
- 2022-02-23
- Details
- Lepu Biopharma Co., Ltd., a biopharmaceutical company, focuses on developing oncology therapeutics with a pipeline designed with a range of oncology products in China. The company develops oncology drug candidates, including antibody-drug conjugates (ADC), oncolytic virus drugs, and immunotherapies. It develops immuno-oncology products, such as HX008 Anti-PD-1 mAb and LP002 Anti-PD-L1 mAb; ADC products, including MRG003 EGFR-targeted ADC, MRG002 HER2-targeted ADC, MRG001 CD20-targeted ADC, MRG004A TF-targeted ADC, and CMG901 CLDNI8.2-targeted ADC; CG0070 oncolytic virus; and other drug candidates, such as HX008+OH2, LP002+OH2, and HX008+LP002. The company was incorporated in 2018 and is headquartered in Shanghai, China.
More Stocks
-
TPS
-
TIG
-
002728
-
ADENADENTRA Inc.
ADEN
-
TPST
-
8957Tokyu REIT, Inc.
8957
-
ISUR
-
600572